NIH
Pubmed
Scroll
down

Publications of 2024

Identification of outcome domains in primary Sjögren's disease: A scoping review by the OMERACT Sjögren disease working group.

Nguyen Y, Beydon M, Foulquier N, Gordon R, Bouillot C, Hammitt KM, Bowman SJ, Mariette X, McCoy SS, Cornec D, Seror R.

Semin Arthritis Rheum. | 2024 Jan 30;65:152385. doi: 10.1016/j.semarthrit.2024.152385. Online ahead of print. PMID: 38340608

Publications of 2023

Immune checkpoints are predominantly co-expressed by clonally expanded CD4+FoxP3+ intratumoral T-cells in primary human cancers.

Bredel D, Tihic E, Mouraud S, Danlos FX, Susini S, Aglave M, Alfaro A, Mohamed-Djalim C, Rouanne M, Halse H, Bigorgne A, Tselikas L, Dalle S, Hartl DM, Baudin E, Guettier C, Vibert E, Rosmorduc O, Robert C, Ferlicot S, Parier B, Albiges L, de Montpreville VT, Besse B, Mercier O, Even C, Breuskin I, Classe M, Radulescu C, Lebret T, Pautier P, Gouy S, Scoazec JY, Zitvogel L, Marabelle A, Bonvalet M.

J Exp Clin Cancer Res. | 2023 Dec 6;42(1):333. doi: 10.1186/s13046-023-02897-6. PMID: 38057799 Free PMC article.

Epidemiology of Sjögren syndrome

Maxime Beydon, Sara McCoy, Yann Nguyen, Takayuki Sumida, Xavier Mariette & Raphaèle Seror

Nat Rev Rheumatol. | 2023 Dec 18. doi: 10.1038/s41584-023-01057-6. PMID: 38110617 Review.

Serum and tissue biomarkers associated with CRESS and STAR response to B-cell targeted therapy in TRACTISS trial of Sjogren's syndrome.

Pontarini E, Sciacca E, Chowdhury F, Grigoriadou S, Rivellese F, Murray-Brown WJ, Lucchesi D, Fossati-Jimack L, Nerviani A, Jaworska E, Ghirardi GM, Giacomassi C, Emery P, Ng WF, Sutcliffe N, Everett CC, Fernandez C, Tappuni AR, Seror R, Mariette X, Porcher R, Cavallaro G, Pulvirenti A, Verstappen G, de Wolff L, Arends S, Bootsma H, Lewis MJ, Pitzalis C, Bowman SJ, Bombardieri M; TRACTISS Study research group.

Arthritis Rheumatol. | 2023 Dec 10. doi: 10.1002/art.42772. Online ahead of print. PMID: 38073013

Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncology.

Alouani E, Laparra A, Perret A, Sakkal M, Messayke S, Danlos FX, Ouali K, Hollebecque A, Even C, Ammari S, Baldini C, Champiat S, Besse B, Robert C, Guettier C, Samuel D, Lambotte O, De Martin E, Michot JM.

Eur J Cancer. | 2023 Nov;193:113313. doi: 10.1016/j.ejca.2023.113313. Epub 2023 Aug 26. PMID: 37748398

Sjögren Syndrome: A Forgotten or an Overdiagnosed Entity?

Mariette X.

J Rheumatol. | 2023 Nov 1:jrheum.2023-0964. doi: 10.3899/jrheum.2023-0964. Online ahead of print. PMID: 37914214

Risk of cancer for patients with rheumatoid arthritis versus general population: a national claims database cohort study.

Maxime Beydon, Sandrine Pinto, Yann De Rycke, Bruno Fautrel, Xavier Mariette, Raphaèle Seror, Florence Tubach et al.

The Lancet Regional Health – Europe. | Open Access Published: October 29, 2023DOI:https://doi.org/10.1016/j.lanepe.2023.100768

Comparison between primary Sjögren's disease patients with high or low level of dryness.

Kachaner A, Bergé E, Desmoulins F, Le Pajolec C, Rousseau A, Labetoulle M, Nocturne G, Mariette X, Seror R.

RMD Open. | 2023 Oct;9(4):e003291. doi: 10.1136/rmdopen-2023-003291. PMID: 37899092 Free PMC article.

Ocular surface toxicities associated with modern anticancer therapies.

Boucher R, Haigh O, Barreau E, Champiat S, Lambotte O, Adam C, Labetoulle M, Rousseau A.

SurvOphthalmol. | 2023 Oct 6:S0039-6257(23)00134-0. doi: 10.1016/j.survophthal.2023.10.002. Online ahead of print. PMID: 37806566 Review.

Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis.

Berry JS, Tarn J, Casement J, Duret PM, Scott L, Wood K, Johnsen SJ, Nordmark G, Devauchelle-Pensec V, Seror R, Fisher B, Barone F, Bowman SJ, Bombardieri M, Lendrem D, Felten R, Gottenberg JE, Ng WF.

Annals of the Rheumatic Diseases | 2023 Sep 1:ard-2023-224503. doi: 10.1136/ard-2023-224503. PMID: 37657927

Liposomal AntagomiR-155-5p restores anti-inflammatory macrophages and improves arthritis in pre-clinical models of Rheumatoid arthritis.

Paoletti A, Ly B, Cailleau C, Gao F, Péan de Ponfilly-Sotier M, Pascaud J, Rivière E, Yang L, Nwosu L, Elmesmari A, Reynaud F, Hita M, Paterson D, Reboud J, Fay F, Nocturne G, Tsapis N, McInnes IB, Kurowska-Stolarska M, Fattal E, Mariette X

Arthritis Rheumatol | 2023 Aug 1. doi: 10.1002/art.42665. PMID: 37527031

Post-transcriptional checkpoints in autoimmunity

Bechara R, Vagner S, Mariette X.

Nature Reviews Rheumatology | 2023 Aug;19(8):486-502. doi: 10.1038/s41584-023-00980-y. Epub 2023 Jun 13. PMID: 37311941 Review.

Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.

Bitoun S, Hässler S, Ternant D, Szely N, Gleizes A, Richez C, Soubrier M, Avouac J, Brocq O, Sellam J, de Vries N, Huizinga TWJ, Jury EC, Manson JJ, Mauri C, Matucci A, Hacein Bey Abina S, Mulleman D, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

JAMA Netw Open | 2023 Jul 3;6(7):e2323098. doi: 10.1001/jamanetworkopen.2023.23098. PMID: 37436748

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.

Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, MbogningFonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L.

Science. | 2023 Jun 9;380(6649):eabo2296. doi: 10.1126/science.abo2296. Epub 2023 Jun 9. PMID: 37289890

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series.

Coustal C, Vanoverschelde J, Quantin X, Lesage C, Michot JM, Lappara A, Ederhy S, Assenat E, Faure M, Issa N, Lambotte O, Puyade M, Dereure O, Tosi D, Rullier P, Serre I, Larcher R, Klouche K, Chanques G, Vernhet-Kovacsik H, Faillie JL, Agullo A, Roubille F, Guilpain P, Maria ATJ.

J Immunother Cancer. | 2023 May;11(5):e004792. doi: 10.1136/jitc-2022-004792. PMID: 37258037

[An overview of immune checkpoint inhibitors toxicities].

Rouvet G, Lambotte O.

Med Sci (Paris). | 2023 May;39(5):445-451. doi: 10.1051/medsci/2023066. Epub 2023 May 23. PMID: 37219349 French.

Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma.

Ascione S, Harel S, Besson FL, Belkhir R, Henry J, Royer B, Arnulf B, Mariette X, Seror R.

Haematologica | 2023 Mar 23. doi: 10.3324/haematol.2022.282214. Online ahead of print. PMID:36951162

Cancer screening in chronic inflammatory rheumatic diseases.

Joanna Kedra, Raphaèle Seror

Joint Bone Spine | 2023 Feb 24:105557. doi: 10.1016/j.jbspin.2023.105557. Online ahead of print.PMID: 36842758

Amphiphilic Phosphorus Dendrons Associated with Anti-inflammatory siRNA Reduce Symptoms in Murine Collagen-Induced Arthritis.

Yu Z, Tsapis N, Fay F, Chen L, Karpus A, Shi X, Cailleau C, García Pérez S, Huang N, Vergnaud J, Mignani S, Majoral JP, Fattal E.

Biomacromolecules | 2023 Feb 13;24(2):667-677. doi: 10.1021/acs.biomac.2c01117. Epub 2023 Jan 4.

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.

Boumaza X, Bonneau B, Roos-Weil D, Pinnetti C, Rauer S, Nitsch L, Del Bello A, Jelcic I, Sühs KW, Gasnault J, Goreci Y, Grauer O, Gnanapavan S, Wicklein R, Lambert N, Perpoint T, Beudel M, Clifford D, Sommet A, Cortese I, Martin-Blondel G; Immunotherapy for PML Study Group.

Ann Neurol. | 2023 Feb;93(2):257-270. doi: 10.1002/ana.26512. Epub 2022 Oct 17.PMID: 36151879 Free PMC article.

Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.

Antoun S, Lanoy E, Ammari S, Farhane S, Martin L, Robert C, Planchard D, Routier E, Voisin AL, Messayke S, Champiat S, Michot JM, Laghouati S, Lambotte O, Marabelle A, Baracos V.

Eur J Cancer. | 2023 Jan;178:49-59. doi: 10.1016/j.ejca.2022.10.013. Epub 2022 Oct 27.PMID: 36403367

Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors.

Velev M, Baroudjian B, Pruvost R, De Martin E, Laparra A, Babai S, Teysseire S, Danlos FX, Albiges L, Bernigaud C, Benderra MA, Pradère P, Zaidan M, Decroisette C, Fallah F, Matergia G, Lavaud P, Jantzem H, Atzenhoffer M, Buyse V, Ammari S, Robert C, Champiat S, Messayke S, Marabelle A, Guettier C, Lebbe C, Lambotte O, Michot JM.

Eur J Cancer. | 2023 Jan;179:28-47. doi: 10.1016/j.ejca.2022.11.001. Epub 2022 Nov 12.PMID: 36473326

Publications of 2022

Using genetics to predict toxicity of cancer immunotherapy

Caroline Robert, Stéphan Vagner & Xavier Mariette

Nature Medicine | volume 28, pages2471–2472 (2022)

Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity

Loïc Meudec, Pauline Richebé, Juliette Pascaud, Xavier Mariette, Gaetane Nocturne

Rheumatology | keac710, https://doi.org/10.1093/rheumatology/keac710

CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia

Awatef Allouch, Laurent Voisin, Yanyan Zhang, Syed Qasim Raza, Yann Lecluse, Julien Calvo, Dorothée Selimoglu-Buet, Stéphane de Botton, Fawzia Louache, Françoise Pflumio, Eric Solary & Jean-Luc Perfettini.

Nature Communications | doi: 10.1038/s41467-022-34548-3 - Article number: 6739 (2022) - 08 November 2022

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.

Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, Texier M.

Cancer Treat Rev. | 2022 Nov;110:102452. doi: 10.1016/j.ctrv.2022.102452. Epub 2022 Aug 10.PMID: 35998515 Free article. Review.

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report.

Aldea M, Belkhir R, Colomba E, Blanchard P, Danlos FX, Botticella A, Terlizzi M, Deutsch E, Le Péchoux C, Planchard D, Michot JM, Besse B, Levy A.

Front Immunol | 2022 Oct 24;13:920130. doi: 10.3389/fimmu.2022.920130. eCollection 2022. PMID: 36353627

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study.

De La Fuente F, Belkhir R, Henry J, Nguyen CD, Pham T, Germain V, Gavand PE, Labadie C, Briere C, Lauret A, Cardon T, Mouterde G, Bonnet I, Rouxel L, Truchetet ME, Schaeverbeke T, Richez C, Kostine M; Club Rhumatismes and Inflammation (CRI).

RMD Open | 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612. PMID: 36270747

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma.

Kedra J, Seror R, Dieudé P, Constantin A, Toussirot E, Kfoury E, Masson C, Cornec D, Dubost JJ, Marguerie L, Ottaviani S, Grados F, Belkhir R, Fain O, Fautrel B, Philippe P, Piperno M, Combe B, Lambotte O, Richez C, Sellam J, Sené T, Denis G, Lequerre T, Lazure T, Mariette X, Nocturne G.

Joint Bone Spine | 2022 Oct;89(5):105390. doi: 10.1016/j.jbspin.2022.105390. Epub 2022 Apr 28. PMID: 35490943

Immune-related adverse events of cancer immunotherapies targeting kinases.

Ramos-Casals M, Flores-Chávez A, Brito-Zerón P, Lambotte O, Mariette X.

Pharmacol Ther | 2022 Sep;237:108250. doi: 10.1016/j.pharmthera.2022.108250. Epub 2022 Jul 14. PMID: 35843306

Machine learning predicts response to TNF inhibitors in rheumatoid arthritis: results on the ESPOIR and ABIRISK cohorts.

Bouget V, Duquesne J, Hassler S, Cournède PH, Fautrel B, Guillemin F, Pallardy M, Broët P, Mariette X, Bitoun S.

RMD Open | 2022 Aug;8(2):e002442. doi: 10.1136/rmdopen-2022-002442. PMID: 35999028

Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database.

Seror R, Lafourcade A, De Rycke Y, Pinto S, Castaneda J, Fautrel B, Mariette X, Tubach F.

RMD Open | 2022 Jun;8(2):e002139. doi: 10.1136/rmdopen-2021-002139. PMID: 35738803

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses.

Bitoun S, Avouac J, Henry J, Ghossan R, Al Tabaa O, Belkhir R, Nocturne G, Mariaggi AA, Rozenberg F, Vauloup-Fellous C, Mariette X, Seror R.

RMD Open | 2022 May;8(1):e002308. doi: 10.1136/rmdopen-2022-002308. PMID: 35589332

Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases.

Bitoun S, Henry J, Desjardins D, Vauloup-Fellous C, Dib N, Belkhir R, Mouna L, Joly C, Bitu M, Ly B, Pascaud J, Seror R, Roque Afonso AM, Le Grand R, Mariette X.

Arthritis Rheumatol | 2022 Jun;74(6):927-933. doi: 10.1002/art.42058. Epub 2022 Mar 29. PMID: 34962357

Features of non-Hodgkin's lymphoma diagnosed in minor salivary gland biopsies from primary Sjögren's syndrome patients.

Parreau S, Nocturne G, Mariette X, Burroni B, Lazure T, Besson FL, Régent A, Mouthon L, Terrier B, Seror R, Le Guern V.

Rheumatology (Oxford) | 2022 Aug 30;61(9):3818-3823. doi: 10.1093/rheumatology/keab949. PMID: 34940802

Interplay between mucus mobility and alveolar macrophage targeting of surface-modified liposomes.

Japiassu KB, Fay F, Marengo A, Louaguenouni Y, Cailleau C, Denis S, Chapron D, Tsapis N, Nascimento TL, Lima EM, Fattal E.

J Control Release | 2022 Dec;352:15-24. doi: 10.1016/j.jconrel.2022.10.006. Epub 2022 Oct 14. PMID: 36209941

Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.

González-Sánchez E, Muñoz-Callejas A, Gómez-Román J, San Antonio E, Marengo A, Tsapis N, Bohne-Japiassu K, González-Tajuelo R, Pereda S, García-Pérez J, Cavagna L, González-Gay MÁ, Vicente-Rabaneda EF, Meloni F, Fattal E, Castañeda S, Urzainqui A

Br J Pharmacol | 2022 Sep;179(18):4534-4548. doi: 10.1111/bph.15898. Epub 2022 Jul 13. PMID:35726496

Improving dexamethasone drug loading and efficacy in treating arthritis through a lipophilic prodrug entrapped into PLGA-PEG nanoparticles.

Simón-Vázquez R, Tsapis N, Lorscheider M, Rodríguez A, Calleja P, Mousnier L, de Miguel Villegas E, González-Fernández Á, Fattal E.

Drug DelivTransl Res | 2022 May;12(5):1270-1284. doi: 10.1007/s13346-021-01112-3. Epub 2022 Jan 6. PMID:34993924Free PMC article

Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors.

Camard M, Besse B, Cariou PL, Massayke S, Laparra A, Noel N, Michot JM, Ammari S, Pavec JL, Lambotte O.

Respir Med Res. | 2022 Nov;82:100969. doi: 10.1016/j.resmer.2022.100969. Epub 2022 Nov 9.PMID: 36370683

Ocular Inflammation Induced by Immune Checkpoint Inhibitors.

Chaudot F, Sève P, Rousseau A, Maria ATJ, Fournie P, Lozach P, Keraen J, Servant M, Muller R, Gramont B, Touhami S, Mahmoud H, Quintart PA, Dalle S, Lambotte O, Kodjikian L, Jamilloux Y.

J Clin Med. | 2022 Aug 25;11(17):4993. doi: 10.3390/jcm11174993.PMID: 36078923 Free PMC article.

[Toxicity of cancer immunotherapies: Traps to not miss, the role of the internist].

Lambotte O.

Rev Med Interne. | 2022 Aug;43(8):459-461. doi: 10.1016/j.revmed.2022.07.002. Epub 2022 Jul 22.PMID: 35879133 French. No abstract available.

Sarcoid-like Granulomatosis Associated with Immune Checkpoint Inhibitors in Melanoma.

Melin A, Routier É, Roy S, Pradere P, Le Pavec J, Pierre T, Chanson N, Scoazec JY, Lambotte O, Robert C.

2022 Jun 14;14(12):2937. doi: 10.3390/cancers14122937.PMID: 35740604 Free PMC article. | Cancers (Basel).

Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective.

Flores-Chávez A, Brito-Zerón P, Retamozo S, Bitoun S, Fisher BA, Liew D, Suijkerbuijk K, Chatzidionysiou K, Suárez-Almazor M, Lambotte O, Mariette X, Ramos-Casals M.

Crit Rev Immunol. | 2022;42(4):21-36. doi: 10.1615/CritRevImmunol.2023047272.PMID: 37022357 Review.

Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.

Panhaleux M, Espitia O, Terrier B, Manson G, Maria A, Humbert S, Godbert B, Perrin J, Achille A, Arrondeau J, Kostine M, Fallet V, Pugnet G, Chaigne B, Champiat S, Laparra A, Danlos FX, Launay D, Penel N, Lambotte O, Michot JM, Forestier A.

Eur J Cancer. | 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19.PMID: 34810048 Clinical Trial.

Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy.

Martin de Fremont G, Belkhir R, Henry J, Voisin AL, Lambotte O, Besson FL, Mariette X, Nocturne G.

Ann Rheum Dis. | 2022 Mar;81(3):e52. doi: 10.1136/annrheumdis-2020-217225. Epub 2020 Mar 18.PMID: 32188691 No abstract available.

Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database.

Nguyễn T, Maria ATJ, Ladhari C, Palassin P, Quantin X, Lesage C, Taïeb G, Ayrignac X, Rullier P, Hillaire-Buys D, Lambotte O, Guilpain P, Faillie JL.

Ann Rheum Dis. | 2022 Feb;81(2):e32. doi: 10.1136/annrheumdis-2020-217018. Epub 2020 Feb 17.PMID: 32066555 Free article. No abstract available.

Publications of 2021

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.

Bitoun S, Henry J, Vauloup-Fellous C, Dib N, Belkhir R, Mouna L, Joly C, Desjardins D, Bitu M, Le Grand R, Seror R, Roque Afonso AM, Mariette X.

J Hematol Oncol | 2021 Oct 13;14(1):166. doi: 10.1186/s13045-021-01183-2. PMID: 34645504

Lymphoma complicating rheumatoid arthritis: results from a French case-control study.

Kedra J, Seror R, Dieudé P, Constantin A, Toussirot E, Kfoury E, Masson C, Cornec D, Dubost JJ, Marguerie L, Ottaviani S, Grados F, Belkhir R, Fain O, Goupille P, Sordet C, Fautrel B, Philippe P, Piperno M, Combe B, Lambotte O, Richez C, Sellam J, Sené T, Denis G, Lequerre T, Lazure T, Mariette X, Nocturne G.

RMD Open | 2021 Sep;7(3):e001698. doi: 10.1136/rmdopen-2021-001698. PMID: 34470830

Long-term exposure to monoclonal anti-TNF is associated with an increased risk of lymphoma in BAFF-transgenic mice.

Nocturne G, Ly B, Paoletti A, Pascaud J, Seror R, Nicco C, Mackay F, Vincent FB, Lazure T, Ferlicot S, Stimmer L, Pascal Q, Roulland S, Krzysiek R, Hacein-Bey S, Batteux F, Mariette X.

Clin Exp Immunol | 2021 Aug;205(2):169-181. doi: 10.1111/cei.13602. Epub 2021 May 30. PMID: 33864242

Main publications from the project leaders pertaining to the FHU CARE

Primary Sjögren's Syndrome.

Mariette X, Criswell LA.

N Engl J Med | 2018 Mar 8;378(10):931-939.

B cells in the pathogenesis of primary Sjögren syndrome.

Nocturne G, Mariette X.

Nat Rev Rheumatol | 2018 Mar;14(3):133-145.

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.

Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, Hollebecque A, Champiat S, Marabelle A, Massard C, Lambotte O.

JAMA Oncol | 2019 Jun 6. doi: 10.1001/jamaoncol.2019.1022.

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.

Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, Poirier-Colame V, Roux A, Becharef S, Formenti S, Golden E, Cording S, Eberl G, Schlitzer A, Ginhoux F, Mani S, Yamazaki T, Jacquelot N, Enot DP, Bérard M, Nigou J, Opolon P, Eggermont A, Woerther PL, Chachaty E, Chaput N, Robert C, Mateus C, Kroemer G, Raoult D, Boneca IG, Carbonnel F, Chamaillard M, Zitvogel L.

Science | 2015 Nov 27;350(6264):1079-84.

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.

Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondragón L, Jacquelot N, Qu B, Ferrere G, Clémenson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G,* Zitvogel L.* (*Co-corresponding authors).

Science | 2018 Jan 5;359(6371):91-97.

Previous Publications related to the research project (not necessarily by members of the FHU CARE)

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F.

Ann Oncol | 2017 Jun 1;28(6):1368-1379

Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease

Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R.

JAMA | 2017 Nov 7;318(17):1679-1686.

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.

Ann Rheum Dis | 2017 Oct;76(10):1747-1750.

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, François H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A.

Ann Oncol | 2016 Apr;27(4):559-74.

Association of the autoimmune disease scleroderma with an immunologic response to cancer

Joseph CG, Darrah E, Shah AA, Skora AD, Casciola-Rosen LA, Wigley FM, Boin F, Fava A, Thoburn C, Kinde I, Jiao Y, Papadopoulos N, Kinzler KW, Vogelstein B, Rosen A.

Science | 2014 Jan 10;343(6167):152-7.